Epb4.2 Activators
In the context of Epb4.2, the selected chemicals mainly function as inhibitors of various signaling pathways that negatively regulate Epb4.2. Chemicals such as Anisomycin and SP600125 act on the JNK pathway, a known regulator of Epb4.2 expression. By influencing the activation or inhibition of JNK, these chemicals can enhance the expression of Epb4.2. Similarly, Y-27632 acts as a Rho kinase (ROCK) inhibitor, and the inhibition of ROCK has been associated with increased Epb4.2 expression.
Additionally, other chemicals including U0126, SB203580, PD98059, LY294002, Wortmannin, Rapamycin, PP2, BAY 11-7082, and MG-132 act on a variety of signaling pathways including MEK, p38 MAPK, ERK, PI3K, mTOR, Src family kinases, NF-kB, and proteasomes respectively. Each of these pathways are known to have inhibitory effects on Epb4.2 expression. Therefore, by inhibiting these pathways, these chemicals can potentially enhance Epb4.2 expression. This demonstrates the complex network of signaling pathways that can influence Epb4.2 and the variety of chemicals that can be utilized to manipulate its expression.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin is a JNK activator affecting the JNK pathway, which is known to regulate the expression of Epb4.2. Enhanced activation of JNK could lead to increased expression of Epb4.2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. As JNK is a negative regulator of Epb4.2, inhibition of JNK may lead to enhanced expression of Epb4.2. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a Rho kinase (ROCK) inhibitor. Inhibition of ROCK leads to upregulation of Epb4.2 expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Inhibition of p38 may upregulate Epb4.2 expression as p38 negatively regulates Epb4.2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an ERK inhibitor. ERK negatively regulates Epb4.2 expression, so its inhibition can lead to upregulated Epb4.2 expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. PI3K negatively regulates Epb4.2 expression, so its inhibition can lead to upregulated Epb4.2 expression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a PI3K inhibitor, similar to LY294002, can also lead to enhanced Epb4.2 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor, and mTOR negatively regulates Epb4.2 expression, so its inhibition can lead to upregulated Epb4.2 expression. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a Src family kinase inhibitor. Src family kinases negatively regulate Epb4.2 expression, so their inhibition can lead to upregulated Epb4.2 expression. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 is a NF-kB inhibitor. NF-kB negatively regulates Epb4.2 expression, so its inhibition can lead to upregulated Epb4.2 expression. | ||||||